Remgro (REM) Investor Update summary
Event summary combining transcript, slides, and related documents.
Investor Update summary
13 Nov, 2025Regulatory and Transaction Update
Competition Commission no longer opposes the transaction after enhanced commitments addressing investment, overlap, and vertical foreclosure concerns, including a pledge to build 1 million homes and invest ZAR 10–12 billion over 5–6 years.
Appeals Court hearing is scheduled, with a decision expected within two months; ICASA approval is pending but not seen as a major hurdle.
BEE shielding will remain above 30%, meeting ICASA licensing requirements, and public interest commitments have been strengthened, including free fibre for public institutions and expanded enterprise development.
Competition Tribunal initially prohibited the transaction; merging parties appealed, with a final ruling expected by 22 July 2025.
Key risks include reduced competition in FWA and FTTH, potential price increases, and vertical foreclosure, with remedies such as divestiture arrangements and transparent purchaser selection.
Transaction Structure and Terms
Maziv is valued at ZAR 36 billion, including Herotel; Vodacom will invest ZAR 6.11 billion in cash and ZAR 4.89 billion in assets.
A pre-implementation dividend of up to ZAR 4.2 billion may be declared, subject to debt/EBITDA falling below 3x.
Vodacom's maximum shareholding in Maziv is capped at 34.95%, with Remgro diluting its stake to facilitate this.
Herotel's remaining 49.93% stake will be acquired at a minimum of ZAR 2.75 billion, with final value based on an independent market valuation.
After the second Herotel transaction, Maziv's equity valuation is ZAR 38.75 billion, with an enterprise value of ZAR 59.6 billion and an EBITDA multiple of 11.49.
Financial Implications and Cash Flows
Remgro expects to receive 57% of the ZAR 4.5 billion dividend, with potential for additional proceeds from the Herotel transaction.
CIVH will use proceeds to reduce preference share debt and retain some cash for future opportunities.
The transaction is expected to improve profitability at the Remgro level due to capital injection and reduced debt.
The implied EV/EBITDA multiple for the transaction is approximately 11.5x, based on trailing twelve-month numbers to March 2025.
Illustrative cash flows show a pre-implementation dividend of up to ZAR 4.2 billion to CIVH, with subsequent equity value adjustments.
Latest events from Remgro
- HEPS expected to rise 36%–41% year-over-year for the six months ended 31 December 2025.REM
H1 2026 TU13 Mar 2026 - Headline earnings down 20%, dividend up 10%, with strong OUTsurance and RCL Foods results.REM
H2 202420 Jan 2026 - All resolutions passed as shareholders engaged on strategy, incentives, and global risks.REM
AGM 202412 Jan 2026 - Portfolio is 63% private, with growth led by Mediclinic and CIVH, and focus on ESG and performance.REM
CMD 202520 Dec 2025 - Headline earnings up 38.7%, INAV per share up 10.3%, and dividend up 20%.REM
H1 20251 Dec 2025 - Headline earnings up 38.6%, ordinary dividend up 30.3%, and balance sheet fully de-geared.REM
H2 202516 Oct 2025